All posts by: Michael Zand

About Michael Zand

Kite and Sagamo Are Partnering on Cell-engineered Treatments for Cancer – Immuno-Oncology News

Continue reading

2018-02-28 NEWS

Immuno-Oncology News

Kite and Sagamo Are Partnering on Cell-engineered Treatments for Cancer
Immuno-Oncology News
While this kind of immunotherapy can treat only one kind of cancer, the partners hope to develop specific treatments for several types. The therapies modify either a patient’s own cells or cells that others donate. The companies hope the donated

Continue reading

2018-02-28 NEWS

The Ohio State University News

Newly discovered CRISPR mechanism may help prevent dangerous errors
The Ohio State University News
COLUMBUS, Ohio—Even as CRISPR gene-editing technology is offering insights into genetic diseases, researchers are discovering new things about how it actually works. In the first of two papers just published in the Journal of the American Chemical
Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease?Labiotech.eu (blog)
Charpentier/Doudna Patent Covering CRISPR-Cas9 Gene Regulation ApplicationsBusiness Wire (press release)

all 3 news articles »

Continue reading

2018-02-28 NEWS

How A Bank Of All The World’s Genetic Codes Hopes To Save Nature
Fast Company
Without their cooperation in putting the biological data into the registry, it will be difficult for the project to move forward successfully. “We’ll probably have to create a consortium such that they’re acting in the public interests appropriate to

Continue reading

2018-02-28 NEWS

FierceBiotech

Inscripta bags $55M+ to push forward full CRISPR suite
FierceBiotech
Inscripta bags $55M+ to push forward full CRISPR suite. by Amirah Al Idrus |. Feb 28, 2018 6:00am. CRISPR. Inscripta’s goal is to enable more players, be they startups or major companies, to enter the CRISPR space. (Stephen Dixon). ShareFacebook
Gene-editing startup Inscripta raises $55.5 millionBusiness Insider
Boulder’s Inscripta raises $55.5MBoulder Daily Camera

all 5 news articles »

Continue reading

2018-02-28 NEWS

Business Wire (press release)

Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease?
Labiotech.eu (blog)
Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by
Charpentier/Doudna Patent Covering CRISPR-Cas9 Gene Regulation ApplicationsBusiness Wire (press release)
Newly discovered CRISPR mechanism may prevent dangerous errorsPhys.Org

all 3 news articles »